Stockreport

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis [Yahoo! Finance]

89bio, Inc.  (ETNB) 
Last 89bio, inc. earnings: 3/18 04:05 pm Check Earnings Report
PDF –Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling and ENLIGHTEN-Cirrhosis in MASH patients with compensated cirrhosis [Read more]